Interní Med. 2008; 10(6): 281-284

Management of the patients with chronic heart failure and decreased renal function

MUDr. Filip Málek1, MUDr. Martin Havrda2
1 Kardiocentrum FN Královské Vinohrady, III. lékařská fakulta Univerzity Karlovy, Praha
2 I. interní klinika FN Královské Vinohrady 3. LF UK, Praha

The prevalence of chronic heart failure and renal insufficency is increasing. The association of heart failure and kidney disease is in the literature described as a “cardiorenal syndrome“. The cardiorenal syndrome has common risk factors of cardiovascular and renal impairment. One of the main principals of the non-pharmacological treatment of the cardiorenal syndrome patients is control of the fluid and salt intake. For the medical therapy of the patients with heart failure and decreased renal function it is necessary to use drug with the evidence of the cardioprotective properties and knowledge of its pharmacokinetics. Management of the patients with the cardiorenal syndrome is realized with the interdisciplinary approach based on the cooperation of cardiologist and nephrologist.

Keywords: Key words: chronic heart failure, impared renal function, non-pharmacological treatment, pharmacotherapy.

Published: July 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F, Havrda M. Management of the patients with chronic heart failure and decreased renal function. Interní Med. 2008;10(6):281-284.
Download citation

References

  1. Agarwal R. Effects of statins on renal function. Am J Cardiol 2006 Mar 1; 97 (5): 748-755. Go to original source... Go to PubMed...
  2. Belonje AM, de Boer RA, Voors AA. Recombinant human epo treatment: Beneficial in chronic kidney disease, chronic heart failure, or both?: Editorial to:, ,Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): Effects on cardiac performance by Pappas et al.". Cardiovasc Drugs Ther 2008; 22 (1): 1-2. Go to original source...
  3. Block GA, Hubert-Shearon TE, Levin NW, et al. Association between serum phosphorus and calcium x phospatase product with mortality in chronic hemodialysis patients: a national study. Am J Kidney 1998, 31: 607-617. Go to original source... Go to PubMed...
  4. Bongartz LG, Cramer MJ, Doevendans PA, et al. The severe cardiorenal syndrome:, Guyton revisited'. Eur Heart J 2005; 26 (1): 11-7. Go to original source... Go to PubMed...
  5. Boxer RS, Dauser DA, Walsh SJ, et al. The association between vitamin D and inflammation with the 6-minute walk and frailty in patients with heart failure. J Am Geriatr Soc 2008; 56 (3): 454-461. Go to original source... Go to PubMed...
  6. Cohen N, Gorelik O, Almoznino-Sarafian D, et al. Renal dysfunction in congestive heart failure, pathophysiological and prognostic significance. Clin Nephrol 2004; 61 (3): 177-184. Go to original source... Go to PubMed...
  7. Drüecke TB, Locatelli F, Clyne N, et al. for the CREATE Investigators normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355 (20): 2071-2084. Go to original source... Go to PubMed...
  8. Eckart KU. Cardiovascular consequences of renal anaemia and erythropoetin therapy. Nephrol Dial Transplant 1999; 14: 1317-1323. Go to original source... Go to PubMed...
  9. Erdman E, Lechat P, Verkenne P, Wiermann H. Results from post-hoc analyses of the CIBIS II trial (The Cardiac Insufficiency Bisoprolol Study II): effect of bisoprolol in high-risk patiens groups with chronic heart failure. Eur J Heart Fail 2001, 3: 469-479. Go to original source... Go to PubMed...
  10. Flather MD, Shibata MC, Coats AJ, et al. SENIORS Investigators Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26 (3): 215-225. Go to original source... Go to PubMed...
  11. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102 (2): 203-210. Go to original source... Go to PubMed...
  12. Jungers P, Qualim Z, Nguyen-Khoa T, et al. Cardioprotection: an essential component for predialysis chronic renal failure treatment. Nephrologie 2003; 24 (2): 79-88. Go to PubMed...
  13. Kraut JA, Kurtz I. Metabolic acidosis of CKD: Diagnosis, clinical characteristics, and treatment. American Journal of Kidney Diseases 2005; 45 (6): 978-993. Go to original source... Go to PubMed...
  14. Málek F, Havrda M. Multidisciplinární přístup v péči o nemocné s kardiorenálním selháním - první zkušenosti. Interní Med. 2006; 11: 447-449.
  15. Maxwell PA, Ong HY, Nicholls DP. Influence of progressive renal dysfunction in chronic heart failure. Eur J Heart Fail 2002, 4: 125-130. Go to original source... Go to PubMed...
  16. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109 (8): 1004-1009. Go to original source... Go to PubMed...
  17. MERIT-HF Study Group. Effect of Metoprolol CR/XL in Chronic Heart Failure. Metoprolol CR/ XL Randomised intervention trial in congestive heart failure. Lancet 1999; 353: 2001-2007. Go to original source...
  18. Packer M, Bristow MR, Cohn JN, et al. For the Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med, 1996, 334: 1349-1355. Go to original source... Go to PubMed...
  19. Palazzuoli A. et al. Effects of beta-erythropoetin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007; (154): 645-715. Go to original source... Go to PubMed...
  20. Pappas KD, Gouva CD, Katopodis, et al. Correction of anemia with erythropoetin in chronic kidney disease (stage 3 or 4): Effects on cardiac performance. Cardiovasc Drugs Ther 2008; 22 (1): 37-44. Go to original source... Go to PubMed...
  21. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wites J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341 (10): 753-755. Go to original source... Go to PubMed...
  22. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, Ahn S, Schron E, Shumaker SA, Sheffield LT. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302. Go to original source... Go to PubMed...
  23. Sarnak MJ, Levey AS, Schoolwerth AC, et al. American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention: Kidney disease as a risk factor for development of cardiovascular disease. Circulation 2003; 108 (17): 2154-2169. Go to original source... Go to PubMed...
  24. Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrom. Circulation 2004; 110: 1514-1517. Go to original source... Go to PubMed...
  25. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003; 138: 917-924. Go to original source... Go to PubMed...
  26. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006, 83 (4): 754-759. Go to original source... Go to PubMed...
  27. Silveberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoetin and intravenous iron for the treatment of anemia of sever, resistant congestive heart failure improves cardiac and renal function and functional class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35: 1737-1744. Go to original source... Go to PubMed...
  28. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 2004; 10 (4): 297-303. Go to original source... Go to PubMed...
  29. The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828. Go to original source...
  30. The CONSENSUS trial study group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316: 1429-35.
  31. The Digitalis investigation group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533. Go to original source... Go to PubMed...
  32. Tonelli N, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005, 112 (17): 2627-2633. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.